Mineralocorticoid receptor antagonists (MRAs) are a central component of contemporary cardiorenal protection in chronic kidney disease (CKD). Classic steroidal MRAs, spironolactone and eplerenone, have long been used to treat hypertension and heart failure and to reduce albuminuria, but their wider use in CKD has been...
R. Agarwal, L. Vogt, Juergen Floege et al.· Clinical Kidney Journal· 0 citations
BACKGROUND
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...
R. Inciardi, J. Ostrominski, B. Claggett et al.· Journal of Cardiac Failure· 0 citations
This review synthesizes contemporary evidence for kidney-protective therapy in adults with DKD, emphasizing that non-pharmacologic measures-blood pressure control, individualized glycemic targets, sodium and protein moderation, structured exercise, weight management, and smoking cessation-should be intensified concurre...
Zurong Zhang, Li Li, Ming Yang et al.· Nephrology, Dialysis and Tra...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
